Navigation Links
Amgen to Present at the Cowen and Company 32nd Annual Healthcare Conference
Date:2/29/2012

THOUSAND OAKS, Calif., Feb. 29, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Cowen and Company 32nd Annual Healthcare Conference on Monday, March 5, 2012 at the Boston Marriott Copley Place, Boston, Mass., beginning at approximately 2:50 p.m. Eastern Standard Time.  Jonathan M. Peacock, executive vice president and chief financial officer at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo:  http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

 


'/>"/>
SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ...
(Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread of "superbugs" ... transport vehicles, an advanced and portable UV germicidal lamp manufactured by ... time. In order to prevent EMS paramedics and ... West Palm Beach Fire Rescue is the first ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... announced that 12-month outcomes data from a subset analysis ... of print in the Journal of Interventional Cardiology ... company,s Genous Stent in diabetic patients, with low definite ... The study investigated the 1,236 diabetic patients from ...
... 23, 2011 NephRx Corporation today announced issuance ... peptide NX002, which currently is in preclinical development ... reported that NX002 had demonstrated significant efficacy when ...  Mucositis is a debilitating and often dose-limiting condition ...
Cached Medicine Technology:Data Published in the Journal of Interventional Cardiology Demonstrate Effectiveness and Safety of OrbusNeich's Genous™ Stent in Diabetic Patients 2Data Published in the Journal of Interventional Cardiology Demonstrate Effectiveness and Safety of OrbusNeich's Genous™ Stent in Diabetic Patients 3NephRx Corp. Awarded New U.S. Patent for Oral Mucositis Agent NX002 2NephRx Corp. Awarded New U.S. Patent for Oral Mucositis Agent NX002 3
(Date:4/24/2014)... one out of three survivors of critical illness, ... The Lancet Respiratory Medicine , and the majority ... mentally. , It is one of the largest ... outcomes of critical care survivors, according to lead ... and it highlights a significant public health issue, ...
(Date:4/24/2014)... National Science Foundation has awarded LSU Health Sciences ... (REU) Site grant in the amount of $295,635. ... from diverse social and educational backgrounds, underrepresented in ... The project will provide students with training ... It will be led by Principal Investigator ...
(Date:4/23/2014)... from Sub-Saharan Africa, Latin America and Caribbean islands ... new research from St. Michael,s Hospital. , The ... of Obstetrics and Gynaecology , assessed the differences ... native-born women in six high-immigration countries Australia ... Valencia) and the United States (California, New Jersey ...
(Date:4/23/2014)... 2014 The American Society for Radiation Oncology (ASTRO) ... Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO ... radiation therapy in the treatment of endometrial cancer. ... May-June 2014 issue of Practical Radiation Oncology ... ASTRO. The full-length guideline is available as an ...
(Date:4/23/2014)... The internal surface area of the gastro-intestinal tract has ... square meters. Scientists at the Sahlgrenska Academy have used ... , "Actually, the inner surface of the gastro-intestinal tract ... says scientist Lars Fndriks. , The digestive tract, which ... through the intestines, has a length of about 5 ...
Breaking Medicine News(10 mins):Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2
... ... Mr. Ohad Goren will function as Pollogen,s CEO. Pollogen recently launched its latest technology- ... action - fat reduction. , ... Tel-Aviv, Israel (PRWEB) April 19, 2010 -- Pollogen Ltd , a ...
... ... accumulated medical records knowledge to offer a full Electronic Medical Records (EMR) data conversion ... ... in healthcare connectivity solutions, now offers a full range of EMR to EMR Data ...
... those who get something lodged in their throat die , ... young children who choke after swallowing a foreign object is ... real, the latest research indicates. , "In such cases, the ... K. Shah, a pediatric otolaryngologist with the Children,s National Medical ...
... first study of vitamin K and Non-Hodgkin lymphoma ... found that people who have higher intakes of vitamin K ... lymphoma. Non-Hodgkin Lymphoma is a cancer of the immune ... United States. At the 101st Annual Meeting ...
... SAN MARCOS, TXStudents, perceptions of their overall experience on ... accomplishments, but research has also found a solid relationship ... perceptions of quality of life. Are campus green spaces ... undergrads? A new study investigating this question revealed some ...
... screening, diagnosis , MONDAY, April 19 (HealthDay News) -- Researchers ... tests could be a sign that patients are at higher ... that in blacks, a common germ boosts the risk of ... often become cancerous. , Both studies are slated to be ...
Cached Medicine News:Health News:Pollogen Ltd. Names Ohad Goren Chief Executive Officer 2Health News:Pollogen Ltd. Names Ohad Goren Chief Executive Officer 3Health News:ELLKAY Launches Electronic Medical Records (EMR) Conversion Division to Healthcare Industry 2Health News:ELLKAY Launches Electronic Medical Records (EMR) Conversion Division to Healthcare Industry 3Health News:Fatal Choking a Real Risk Among Toddlers 2Health News:Fatal Choking a Real Risk Among Toddlers 3Health News:Vitamin K may protect against developing non-Hodgkin's lymphoma, say Mayo Clinic researchers 2Health News:Vitamin K may protect against developing non-Hodgkin's lymphoma, say Mayo Clinic researchers 3Health News:Campus green space more important for undergrads 2Health News:New Risk Factors for Colon Cancer Studied 2
Image Diagnostics' Aspect100U is specifically designed for ease of use and high quality image outcome during urological procedures. Aspect tables benefit from a trim, lightweight design, ensuring a s...
The design of this table top is based on advanced functionality for specific urological requirements. This composite product sets a new standard for urological imaging....
... A revolutionary urological imaging ... benefits that translate into improved ... x 1k imaging technology physicians ... to see more anatomical detail ...
Drew Scientific has been making leading edge and top quality CBC systems for over 15 years.,The Excell 16/18 offers a reliable alternative for a 3 part differential....
Medicine Products: